IBM and Nvidia move quantum processors into supercomputing workflows
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
AI / NEWS BRIEF
GPT-6 Rosalind brings Astra-class reasoning into a restricted biology deployment with higher pricing, organizational approval and additional safeguards.
OpenAI released GPT-6 Rosalind Research for multistep biology, drug-discovery and translational-medicine work. The system card says it uses the same weights as GPT-6 Astra, with no additional training data or post-training for this release. Its distinction is the product purpose, access regime and safeguard configuration rather than a newly trained biological foundation model. The API identifier is gpt-6-rosalind.
The model is rolling out to a limited set of approved Research organizations in Work, Codex and the API; it is not available in the ordinary Chat tab. Enterprise access begins with a two-week Admin Preview and is off by default. OpenAI lists standard API pricing of $15 per million input tokens, $75 per million output tokens and $1.50 per million cached input tokens—three times the corresponding GPT-5.5 Rosalind Research rates.
OpenAI classifies the deployment as High capability in the Biological and Chemical domain, below its Critical threshold, and says it retains boundaries against biological weaponization. Those are OpenAI's Preparedness Framework assessments, not independent safety certification. Restricted access reflects both potential scientific value and dual-use risk. The release does not create a REVAL result; AIQuantumScore would need authorized access and a completed evaluation of the exact deployment before publishing one.
New Slurm integration, a Fermilab co-design platform and GPU-accelerated error-correction tools aim to make quantum processors usable inside established HPC environments.
OpenAI has released healthcare-focused computer-use capabilities across its API and clinical products, with configurable approvals, audit logs and new performance results that remain provider-reported.